leadf
logo-loader
viewVentriPoint Diagnostics Ltd.

VentriPoint Diagnostics reports that its new approved heart technology being used by internationally renowned pediatric cardiologist

Earlier this week, the firm said its VMS+ software had been approved for analyzing 3D echo images

1542722237_surgeon.jpg
The firm's tech is being used by a renowned pediatric cardiologist (not pictured)

Medtech group VentriPoint Diagnostics Ltd (CVE:VPT) gave another operational update on Tuesday, saying its VMS+ technology for the heart was now being used for analysis of the left ventricle as well as the right by an internationally renowned pediatric cardiologist in Germany.

As reported earlier this week, Ventripoint extended its reach into the heart imaging market as it revealed its VMS+ software had been approved for analyzing 3D echo images generated by any commercially available 3D echocardiography system.

READ: VentriPoint Diagnostics' heart monitoring tech further boosted by agreement with Canadian government

Renowned Dr Kai Thorsten Laser has now begun using the VMS+ software for 3-D echo analysis of the left ventricle at the HDZ NRW Heart and Diabetes Center in Germany, the firm said in a regulatory release Tuesday.

"We have experienced very positive results and accuracy using Ventripoint's VMS+ system on the right ventricle," said Dr Thorsten Laser.

"We now look forward to performing 3D analysis to validate accuracy of volumes of the left ventricle and in turn, improve cardiac patient care," he added.

Now that the company's software has been approved for all four chambers of the heart, the hospital will be using the Ventripoint VMS+ system for left ventricular volume analysis, particularly for pediatric patients.

There are many potential applications for this innovative technology, the firm says, which provides confidence in the volumetric measurements of patients with accuracy comparable to cardiac MRI.

Shares in Toronto were unchanged at $0.185.

Contact Giles Gwinnett at giles@proactiveinvestors.com

Follow Giles on Twitter @Gile74

Quick facts: VentriPoint Diagnostics Ltd.

Price: 0.095 CAD

TSX-V:VPT
Market: TSX-V
Market Cap: $6.62 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VentriPoint Diagnostics Ltd. named herein, including the promotion by the Company of VentriPoint Diagnostics Ltd. in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Full interview: Ventripoint Diagnostic focussing on sales in 2020 as they...

Ventripoint Diagnostics (CVE:VPT-OTCQB: VPTDF) Executive Chairman and Acting CEO Dr George Adams sat down with Steve Darling from Proactive in Vancouver with news the company has 11 purchase orders in for their echocardiogram system that provides cardiac measurements. Adams telling Proactive...

on 20/2/20

2 min read